HC Wainwright Reiterates Neutral Rating for Kodiak Sciences (NASDAQ:KOD)

Kodiak Sciences (NASDAQ:KODGet Free Report)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective would suggest a potential downside of 45.75% from the company’s previous close.

Kodiak Sciences Trading Up 4.3 %

Shares of NASDAQ KOD opened at $5.53 on Friday. Kodiak Sciences has a one year low of $1.89 and a one year high of $7.77. The business has a 50-day moving average price of $3.36 and a two-hundred day moving average price of $3.05. The firm has a market capitalization of $290.99 million, a PE ratio of -1.52 and a beta of 2.26.

Kodiak Sciences (NASDAQ:KODGet Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01. Research analysts anticipate that Kodiak Sciences will post -3.52 EPS for the current year.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors have recently modified their holdings of KOD. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Kodiak Sciences during the first quarter worth $68,000. Sei Investments Co. purchased a new stake in shares of Kodiak Sciences during the 1st quarter worth about $595,000. Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at about $50,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Kodiak Sciences in the 1st quarter valued at approximately $86,000. Finally, Vanguard Group Inc. grew its stake in shares of Kodiak Sciences by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock valued at $8,702,000 after buying an additional 10,978 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Recommended Stories

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.